And copay accumulator bans continue to spread across the country ... but does it matter?
And I have a survey on what conferences you attend ... I’d be grateful for your input
It's a day of quick hits ... here's to a great weekend
Plus a link to the first-ever ‘Launch Price Communication Report’
And Novo moves to start selling Wegovy directly to patients at $499 a month
And quantifying how the move from copays to coinsurance is driving up OOPs on ‘negotiated’ drugs
And Mesoblast unveils the price for its stem-cell therapy with a noteworthy amount of transparency around value
Plus a couple of links on Elon Musk’s heel turn on health care
But UCB -- bucking the trend -- released its annual numbers: net prices are down, rebates are up
Plus some musings on when or how the 340B debate intersects with legislative pushes around Medicaid
And a J&J lawsuit over biosimilars is the first shot in the war against PBM-backed pseudo-pharma companies
Plus a look at how the price of SpringWorks’ Gomelki was disclosed
